MD Magazine |
Reslizumab Positively Impacts the Quality of Life in Severe Asthma
MD Magazine Previous phase III trials have shown that reslizumab, an investigational IgG4/k humanized monoclonal antibody, improved lung function and reduced asthma exacerbations. Now Joshua Jacobs, MD, from Allergy and Asthma Clinical Research in Walnut … |
View full post on asthma – Google News